Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Endometriosis HELP
Based on 7,109 articles published since 2008
||||

These are the 7109 published articles about Endometriosis that originated from Worldwide during 2008-2018.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline World Endometriosis Society consensus on the classification of endometriosis. 2017

Johnson, Neil P / Hummelshoj, Lone / Adamson, G David / Keckstein, Jörg / Taylor, Hugh S / Abrao, Mauricio S / Bush, Deborah / Kiesel, Ludwig / Tamimi, Rulla / Sharpe-Timms, Kathy L / Rombauts, Luk / Giudice, Linda C / Anonymous351149. ·World Endometriosis Society, Vancouver, Canada. · Robinson Research Institute, University of Adelaide, Australia. · University of Auckland, Auckland, New Zealand. · Repromed Auckland and Auckland Gynaecology Group, Auckland, New Zealand. · World Endometriosis Research Foundation, London, England. · Palo Alto Medical Foundation, Fertility Physicians of Northern California, USA. · KABEG Landeskrankenhaus, Villach, Austria. · Yale School of Medicine, New Haven, USA. · Sao Paulo University, Sao Paulo, Brazil. · Endometriosis New Zealand, Christchurch, New Zealand. · University of Münster School of Medicine, Münster, Germany. · Harvard TH Chan School of Public Health, Boston, USA. · University of Missouri, Columbia, USA. · Monash University, Melbourne, Australia. · University of California San Francisco, San Francisco, USA. ·Hum Reprod · Pubmed #27920089.

ABSTRACT: STUDY QUESTION: What is the global consensus on the classification of endometriosis that considers the views of women with endometriosis? SUMMARY ANSWER: We have produced an international consensus statement on the classification of endometriosis through systematic appraisal of evidence and a consensus process that included representatives of national and international, medical and non-medical societies, patient organizations, and companies with an interest in endometriosis. WHAT IS KNOWN ALREADY: Classification systems of endometriosis, developed by several professional organizations, traditionally have been based on lesion appearance, pelvic adhesions, and anatomic location of disease. One system predicts fertility outcome and none predicts pelvic pain, response to medications, disease recurrence, risks for associated disorders, quality of life measures, and other endpoints important to women and health care providers for guiding appropriate therapeutic options and prognosis. STUDY DESIGN, SIZE, DURATION: A consensus meeting, in conjunction with pre- and post-meeting processes, was undertaken. PARTICIPANTS/MATERIALS, SETTING, METHODS: A consensus meeting was held on 30 April 2014 in conjunction with the World Endometriosis Society's 12th World Congress on Endometriosis. Rigorous pre- and post-meeting processes, involving 55 representatives of 29 national and international, medical and non-medical organizations from a range of disciplines, led to this consensus statement. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 28 consensus statements were made. Of all, 10 statements had unanimous consensus, however none of the statements was made without expression of a caveat about the strength of the statement or the statement itself. Two statements did not achieve majority consensus. The statements covered women's priorities, aspects of classification, impact of low resources, as well as all the major classification systems for endometriosis. Until better classification systems are developed, we propose a classification toolbox (that includes the revised American Society for Reproductive Medicine and, where appropriate, the Enzian and Endometriosis Fertility Index staging systems), that may be used by all surgeons in each case of surgery undertaken for women with endometriosis. We also propose wider use of the World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonisation Project surgical and clinical data collection tools for research to improve classification of endometriosis in the future, of particular relevance when surgery is not undertaken. LIMITATIONS, REASONS FOR CAUTION: This consensus process differed from that of formal guideline development, although based on the same available evidence. A different group of international experts from those participating in this process may have yielded subtly different consensus statements. WIDER IMPLICATIONS OF THE FINDINGS: This is the first time that a large, global, consortium-representing 29 major stake-holding organizations, from 19 countries - has convened to systematically evaluate the best available evidence on the classification of endometriosis and reach consensus. In addition to 21 international medical organizations and companies, representatives from eight national endometriosis organizations were involved, including lay support groups, thus generating and including input from women who suffer from endometriosis in an endeavour to keep uppermost the goal of optimizing quality of life for women with endometriosis. STUDY FUNDING/COMPETING INTERESTS: The World Endometriosis Society convened and hosted the consensus meeting. Financial support for participants to attend the meeting was provided by the organizations that they represented. There was no other specific funding for this consensus process. Mauricio Abrao is an advisor to Bayer Pharma, and a consultant to AbbVie and AstraZeneca; G David Adamson is the Owner of Advanced Reproductive Care Inc and Ziva and a consultant to Bayer Pharma, Ferring, and AbbVie; Deborah Bush has received travel grants from Fisher & Paykel Healthcare and Bayer Pharmaceuticals; Linda Giudice is a consultant to AbbVie, Juniper Pharmaceutical, and NextGen Jane, holds research grant from the NIH, is site PI on a clinical trial sponsored by Bayer, and is a shareholder in Merck and Pfizer; Lone Hummelshoj is an unpaid consultant to AbbVie; Neil Johnson has received conference expenses from Bayer Pharma, Merck-Serono, and MSD, research funding from AbbVie, and is a consultant to Vifor Pharma and Guerbet; Jörg Keckstein has received a travel grant from AbbVie; Ludwig Kiesel is a consultant to Bayer Pharma, AbbVie, AstraZeneca, Gedeon Richter, and Shionogi, and holds a research grant from Bayer Pharma; Luk Rombauts is an advisor to MSD, Merck Serono, and Ferring, and a shareholder in Monash IVF. The following have declared that they have nothing to disclose: Kathy Sharpe Timms; Rulla Tamimi; Hugh Taylor. TRIAL REGISTRATION NUMBER: N/A.

2 Guideline Committee Opinion No. 663 Summary: Aromatase Inhibitors in Gynecologic Practice. 2016

Anonymous1930869. · ·Obstet Gynecol · Pubmed #27214185.

ABSTRACT: Aromatase inhibitors have been used for the treatment of breast cancer, ovulation induction, endometriosis, and other estrogen-modulated conditions. For women with breast cancer, bone mineral density screening is recommended with long-term aromatase inhibitor use because of risk of osteoporosis due to estrogen deficiency. Based on long-term adverse effects and complication safety data, when compared with tamoxifen, aromatase inhibitors are associated with a reduced incidence of thrombosis, endometrial cancer, and vaginal bleeding. For women with polycystic ovary syndrome and a body mass index greater than 30, letrozole should be considered as first-line therapy for ovulation induction because of the increased live birth rate compared with clomiphene citrate. Lifestyle changes that result in weight loss should be strongly encouraged. Aromatase inhibitors are a promising therapeutic option that may be helpful for the management of endometriosis-associated pain in combination therapy with progestins.

3 Guideline ESHRE guideline: management of women with endometriosis. 2014

Dunselman, G A J / Vermeulen, N / Becker, C / Calhaz-Jorge, C / D'Hooghe, T / De Bie, B / Heikinheimo, O / Horne, A W / Kiesel, L / Nap, A / Prentice, A / Saridogan, E / Soriano, D / Nelen, W / Anonymous940782. ·Department of Obstetrics & Gynaecology, Research Institute GROW, Maastricht University Medical Centre, PO Box 5800, 6202 AZ Maastricht, The Netherlands. ·Hum Reprod · Pubmed #24435778.

ABSTRACT: STUDY QUESTION: What is the optimal management of women with endometriosis based on the best available evidence in the literature? SUMMARY ANSWER: Using the structured methodology of the Manual for ESHRE Guideline Development, 83 recommendations were formulated that answered the 22 key questions on optimal management of women with endometriosis. WHAT IS KNOWN ALREADY: The European Society of Human Reproduction and Embryology (ESHRE) guideline for the diagnosis and treatment of endometriosis (2005) has been a reference point for best clinical care in endometriosis for years, but this guideline was in need of updating. STUDY DESIGN, SIZE, DURATION: This guideline was produced by a group of experts in the field using the methodology of the Manual for ESHRE Guideline Development, including a thorough systematic search of the literature, quality assessment of the included papers up to January 2012 and consensus within the guideline group on all recommendations. To ensure input from women with endometriosis, a patient representative was part of the guideline development group. In addition, patient and additional clinical input was collected during the scoping and review phase of the guideline. PARTICIPANTS/MATERIALS, SETTING, METHODS: NA. MAIN RESULTS AND THE ROLE OF CHANCE: The guideline provides 83 recommendations on diagnosis of endometriosis and on the treatment of endometriosis-associated pain and infertility, on the management of women in whom the disease is found incidentally (without pain or infertility), on prevention of recurrence of disease and/or painful symptoms, on treatment of menopausal symptoms in patients with a history of endometriosis and on the possible association of endometriosis and malignancy. LIMITATIONS, REASONS FOR CAUTION: We identified several areas in care of women with endometriosis for which robust evidence is lacking. These areas were addressed by formulating good practice points (GPP), based on the expert opinion of the guideline group members. WIDER IMPLICATIONS OF THE FINDINGS: Since 32 out of the 83 recommendations for the management of women with endometriosis could not be based on high level evidence and therefore were GPP, the guideline group formulated research recommendations to guide future research with the aim of increasing the body of evidence. STUDY FUNDING/COMPETING INTEREST(S): The guideline was developed and funded by ESHRE, covering expenses associated with the guideline meetings, with the literature searches and with the implementation of the guideline. The guideline group members did not receive payment. All guideline group members disclosed any relevant conflicts of interest (see Conflicts of interest). TRIAL REGISTRATION NUMBER: NA.

4 Guideline [The statement of Polish Society's Experts Group concerning diagnostics and methods of endometriosis treatment]. 2012

Basta, Antoni / Brucka, Aleksandra / Górski, Jarosław / Kotarski, Jan / Kulig, Bartosz / Oszukowski, Przemysław / Poreba, Ryszard / Radowicki, Stanisław / Radwan, Jerzy / Sikora, Jerzy / Skret, Andrzej / Skrzypczak, Jana / Szyłło, Krzysztof / Anonymous2000749. · ·Ginekol Pol · Pubmed #23379199.

ABSTRACT: Endometriosis is defined by endometrial glands and stroma outside of the endometrial cavity Three types of endometriosis have been described: peritoneal endometriosis, ovarian endometriosis and deep infiltrating endometriosis. Endometriosis afflicts 6-15% of women population. It occurs mainly in the group of women in reproductive age, but also in the group of minors and approximately 3% of women after menopause. Within the group of women suffering from infertility the frequency of endometriosis increased to 35-50% of cases. Endometriosis is associated with pain symptoms which can bear the character of pain occurring periodically and altering into constant pain, dysmenorrhea, dyspareunia, dysuria and dyschezia. The correlation between the stage of endometriosis and intensity of pain symptoms not always has to be proportionate. Laparoscopy can be perceived as a standard procedure in endometriosis diagnostics as it allows simultaneous treatment. Profound interview as well as visual diagnostics (USG, MRI) should precede laparoscopy Treatment of endometriosis can be divided into pharmacological and surgical treatment, which can be invasive or non-invasive. The type of treatment depends on patient's age and her procreation plans, occurring ailments and endometriosis type. Important role is played by adjuvant treatment such as appropriate diet and lifestyle. Treatment of advanced endometriosis should be conducted in reference centres that are appointed with adequate equipment and have the possibility of interdisciplinary treatment. Presented standards can digest and outline the order of proceedings both in diagnostics and endometriosis treatment. The research group believes that the above compilation will facilitate undertaking appropriate decision in diagnosis and treatment of the disease, which will subsequently contribute to therapeutic success.

5 Guideline [Diagnosis and treatment of endometriosis]. 2011

Anonymous1350713. · ·Ginecol Obstet Mex · Pubmed #22168117.

ABSTRACT: -- No abstract --

6 Guideline Endometriosis: diagnosis and management. 2010

Leyland, Nicholas / Casper, Robert / Laberge, Philippe / Singh, Sukhbir S / Anonymous4440693. · ·J Obstet Gynaecol Can · Pubmed #21545757.

ABSTRACT: OBJECTIVE: To improve the understanding of endometriosis and to provide evidence-based guidelines for the diagnosis and management of endometriosis. OUTCOMES: OUTCOMES evaluated include the impact of the medical and surgical management of endometriosis on women's experience of morbidity and infertility. METHODS: Members of the guideline committee were selected on the basis of individual expertise to represent a range of practical and academic experience in terms of both location in Canada and type of practice, as well as subspecialty expertise along with general gynaecology background. The committee reviewed all available evidence in the English and French medical literature and available data from a survey of Canadian women. Recommendations were established as consensus statements. The final document was reviewed and approved by the Executive and Council of the SOGC. RESULTS: This document provides a summary of up-to-date evidence regarding diagnosis, investigations, and medical and surgical management of endometriosis. The resulting recommendations may be adapted by individual health care workers when serving women with this condition. CONCLUSIONS: Endometriosis is a common and sometimes debilitating condition for women of reproductive age. A multidisciplinary approach involving a combination of lifestyle modifications, medications, and allied health services should be used to limit the impact of this condition on activities of daily living and fertility. In some circumstances surgery is required to confirm the diagnosis and provide therapy to achieve the desired goal of pain relief or improved fecundity. Women who find an acceptable management strategy for this condition may have an improved quality of life or attain their goal of successful pregnancy. EVIDENCE: Medline and Cochrane databases were searched for articles in English and French on subjects related to endometriosis, pelvic pain, and infertility from January 1999 to October 2009 in order to prepare a Canadian consensus guideline on the management of endometriosis. VALUES: The quality of evidence was rated with use of the criteria described by the Canadian Task Force on Preventive Health Care. Recommendations for practice were ranked according to the method described by the Task Force. See Table 1. BENEFITS, HARMS, AND COSTS: Implementation of the guideline recommendations will improve the care of women with pain and infertility associated with endometriosis.

7 Guideline EMAS position statement: Managing the menopause in women with a past history of endometriosis. 2010

Moen, Mette H / Rees, Margaret / Brincat, Marc / Erel, Tamer / Gambacciani, Marco / Lambrinoudaki, Irene / Schenck-Gustafsson, Karin / Tremollieres, Florence / Vujovic, Svetlana / Rozenberg, Serge / Anonymous7370665. ·Department of Laboratory Medicine, Children's and Women's Health, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway. mette.moen@ntnu.no ·Maturitas · Pubmed #20627430.

ABSTRACT: INTRODUCTION: Endometriosis is a common disease in women of reproductive age. The symptoms usually disappear after a natural or a surgical menopause. Estrogen-based hormone therapy is required in women with premature or early menopause until the average age of the natural menopause and should be considered in older women with severe climacteric symptoms. However use of hormone therapy raises concerns about disease recurrence with pain symptoms, need for surgery and possibly malignant transformation of residual endometriosis. AIM: To formulate a position statement on the management of the menopause in women with a past history of endometriosis. MATERIALS AND METHODS: Literature review and consensus of expert opinion. RESULTS AND CONCLUSIONS: The data regarding hormone therapy regimens are limited. However it may be safer to give either continuous combined estrogen-progestogen therapies or tibolone in both hysterectomised and nonhysterectomised women as the risk of recurrence may be reduced. The risk of recurrence with hormone therapy is probably increased in women with residual disease after surgery. Management of potential recurrence is best monitored by responding to recurrence of symptoms. Women not wanting estrogen or those who are advised against should be offered alternative pharmacological treatment for climacteric symptoms or skeletal protection if indicated. Herbal preparations should be avoided as their efficacy is uncertain and some may contain estrogenic compounds.

8 Guideline ACOG Practice Bulletin No. 110: noncontraceptive uses of hormonal contraceptives. 2010

Anonymous5950646. · ·Obstet Gynecol · Pubmed #20027071.

ABSTRACT: -- No abstract --

9 Guideline Diagnostic laparoscopy guidelines : This guideline was prepared by the SAGES Guidelines Committee and reviewed and approved by the Board of Governors of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), November 2007. 2008

Hori, Yumi / Anonymous2180596. ·Society of American Gastrointestinal and Endoscopic Surgeons, 11300 West Olympic Blvd, Suite 600, Los Angeles, CA 90064, USA. sagesweb@sages.org ·Surg Endosc · Pubmed #18389320.

ABSTRACT: -- No abstract --

10 Editorial Toward minimally disruptive management of symptomatic endometriosis: reducing low-value care and the burden of treatment. 2018

Vercellini, Paolo / Frattaruolo, Maria Pina / Buggio, Laura. ·a Department of Clinical Sciences and Community Health , Università degli Studi di Milano , Milan , Italy. · b Department of Health of Woman, Child, and Newborn , Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico , Milan , Italy. ·Expert Rev Pharmacoecon Outcomes Res · Pubmed #29186995.

ABSTRACT: -- No abstract --

11 Editorial [How to improve endometriosis management]. 2017

Daraï, Emile / Chabbert-Buffet, Nathalie. ·AP-HP, université Pierre-et-Marie-Curie Paris 6, hôpital Tenon, service de gynécologie-obstétrique et reproduction humaine, 4, rue de la Chine, 75020 Paris, France; Centre expert en endométriose (C3E), Groupe de recherche clinique (GRC-6 UPMC), inserm UMRS-938, France. Electronic address: emile.darai@aphp.fr. · AP-HP, université Pierre-et-Marie-Curie Paris 6, hôpital Tenon, service de gynécologie-obstétrique et reproduction humaine, 4, rue de la Chine, 75020 Paris, France; Centre expert en endométriose (C3E), Groupe de recherche clinique (GRC-6 UPMC), inserm UMRS-938, France. ·Presse Med · Pubmed #29224704.

ABSTRACT: -- No abstract --

12 Editorial An Oral GnRH Antagonist for Endometriosis - A New Drug for an Old Disease. 2017

Hornstein, Mark D. ·From the Department of Obstetrics and Gynecology, Brigham and Women's Hospital and Harvard Medical School, Boston. ·N Engl J Med · Pubmed #28679085.

ABSTRACT: -- No abstract --

13 Editorial Clinical dynamics of Dienogest for the treatment of endometriosis: from bench to bedside. 2017

Laganà, Antonio Simone / Vitale, Salvatore Giovanni / Granese, Roberta / Palmara, Vittorio / Ban Frangež, Helena / Vrtačnik-Bokal, Eda / Chiofalo, Benito / Triolo, Onofrio. ·a Unit of Gynecology and Obstetrics, Department of Human Pathology in Adulthood and Childhood 'G. Barresi' , University of Messina , Messina , Italy. · b Department of Reproduction , University Medical Center Ljubljana , Ljubljana , Slovenia. ·Expert Opin Drug Metab Toxicol · Pubmed #28537213.

ABSTRACT: -- No abstract --

14 Editorial New Lessons about Endometriosis - Somatic Mutations and Disease Heterogeneity. 2017

Montgomery, Grant W / Giudice, Linda C. ·From the Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia (G.W.M.); and the Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, San Francisco (L.C.G.). ·N Engl J Med · Pubmed #28489997.

ABSTRACT: -- No abstract --

15 Editorial Bladder Endometriosis: A Rare but Challenging Condition. 2017

Fauconnier, Arnaud / Aubry, Gabrielle / Fritel, Xavier. ·Department of Gynecology and Obstetrics, Centre Hospitalier Intercommunal de Poissy-Saint-Germain-en-Laye, Poissy, France; Research Unit "Risk and Safety in Clinical Medicine for Women and Perinatal Health", Versailles-Saint-Quentin University, Montigny-le-Bretonneux, France. Electronic address: afauconnier@chi-poissy-st-germain.fr. · Research Unit "Risk and Safety in Clinical Medicine for Women and Perinatal Health", Versailles-Saint-Quentin University, Montigny-le-Bretonneux, France. · INSERM CIC802, Poitiers University, University Hospital of Poitiers, Poitiers, France. ·Eur Urol · Pubmed #28129892.

ABSTRACT: -- No abstract --

16 Editorial Endometriosis: Modern management of an ancient disease. 2017

Ferrero, Simone. ·Academic Unit of Obstetrics and Gynaecology, IRCCS AOU San Martino - IST, Largo R. Benzi 10, 16132 Genoa, Italy; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Italy. Electronic address: simone.ferrero@unige.it. ·Eur J Obstet Gynecol Reprod Biol · Pubmed #28094070.

ABSTRACT: -- No abstract --

17 Editorial Postoperative hormonal therapy after surgical excision of deep endometriosis. 2017

Somigliana, Edgardo / Busnelli, Andrea / Benaglia, Laura / Viganò, Paola / Leonardi, Marta / Paffoni, Alessio / Vercellini, Paolo. ·Obstet-Gynecol Dept, Fondazione Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy. Electronic address: dadosomigliana@yahoo.it. · Obstet-Gynecol Dept, Fondazione Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy; Università degli Studi di Milano, Milan, Italy. · Obstet-Gynecol Dept, Fondazione Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy. · Obstet-Gynecol Dept, San Raffaele Scientific Institute, Milan, Italy. ·Eur J Obstet Gynecol Reprod Biol · Pubmed #27067871.

ABSTRACT: The clinical management of women with deep peritoneal endometriosis remains controversial. The debate focuses mainly on the precise role of hormonal medical treatment and surgery and on the most suitable surgical technique to be used. In particular, considering the risks of second-line surgery, prevention of recurrences after first-line surgery is a priority in this context. Post-surgical medical therapy has been advocated to improve the effectiveness of surgery and prevent recurrences. However, adjuvant therapy, i.e. a short course of 3-6 months of hormonal therapy after surgery, has been proven to be of limited or no benefit for endometriosis in general and for deep peritoneal endometriosis in particular. On the other hand, two cohort studies suggest a beneficial effect of prolonged hormonal therapy after surgery for deep endometriosis. Even if this evidence is too weak to confidently advocate systematic administration of prolonged medical therapy after surgery, we argue in favour of this approach because of the strong association of deep endometriosis with other disease forms. In fact, women operated on for deep endometriosis may also face recurrences of endometriomas, superficial peritoneal lesions and pelvic pain in general. The demonstrated high effectiveness of prolonged postoperative therapy for the prevention of endometriomas' formation and dysmenorrhea recurrence should thus receive utmost consideration in the decision-making process.

18 Editorial The Impact of Endometriosis on the Health of Women 2016. 2016

Mettler, Liselotte / Schmidt, Dietmar / Maher, Peter. ·Department of Obstetrics and Gynecology, University Clinics of Schleswig-Holstein, Arnold Heller Strasse 3/24, 24105 Kiel, Germany. · Institute of Pathology, Gereonstr. 14a, 41747 Viersen, Germany. · Department of Endosurgery, Mercy Hospital for Women, Heidelberg, VIC 3084, Australia. ·Biomed Res Int · Pubmed #27882319.

ABSTRACT: -- No abstract --

19 Editorial Visceral factors in rehabilitation & health. 2016

Sorenson, Matthew / Wallden, Matt. ·United Kingdom. Electronic address: mattwallden@gmail.com. ·J Bodyw Mov Ther · Pubmed #27814875.

ABSTRACT: -- No abstract --

20 Editorial [Information to patients in endometriosis: We must stop the frightening machine!] 2016

Canis, M / Curinier, S / Campagne-Loiseau, S / Kaemerlen Rabischong, A G / Rabischong, B / Pouly, J L / Grémeau, A S / Botchorishvili, R / Bourdel, N. ·Department of gynecologic surgery, CHU Estaing, 1, place Lucie-et-Raymond-Aubrac, 63000 Clermont-Ferrand, France. Electronic address: mcanis@chu-clermontferrand.fr. · Department of gynecologic surgery, CHU Estaing, 1, place Lucie-et-Raymond-Aubrac, 63000 Clermont-Ferrand, France. ·Gynecol Obstet Fertil · Pubmed #27765429.

ABSTRACT: -- No abstract --

21 Editorial [Ovarian endometriomas: No-surgery has never been evaluated and surgery correctly performed should remain the gold-standard!] 2016

Canis, M / Botchorishvili, R / Bourdel, N / Chauffour, C / Gremeau, A-S / Rabischong, B / Campagne, S / Pouly, J-L / Matsuzaki, S. ·Department of Gynecologic Surgery, CHU Estaing, 1, place Lucie-et-Raymond-Aubrac, 63000 Clermont-Ferrand, France. Electronic address: mcanis@chu-clermontferrand.fr. · Department of Gynecologic Surgery, CHU Estaing, 1, place Lucie-et-Raymond-Aubrac, 63000 Clermont-Ferrand, France. ·Gynecol Obstet Fertil · Pubmed #27751749.

ABSTRACT: -- No abstract --

22 Editorial Editorial: Childbirth and Reproduction. 2016

Williams, Gareth / Jones, Ian Rees. ·School of Social Sciences, Cardiff University, UK. ·Sociol Health Illn · Pubmed #27283390.

ABSTRACT: -- No abstract --

23 Editorial [The Endometriosis Fertility Index (EFI) is simple to use]. 2016

Boujenah, J / Poncelet, C / Madelenat, P. ·Pôle femme et enfant, groupe hospitalier universitaire Paris Seine-Saint-Denis, site Jean-Verdier, avenue du 14-Juillet, 93140 Bondy, France; UFR SMBH, université Paris 13, Sorbonne Paris-Cité, 93000 Bobigny, France. Electronic address: jeremy.boujenah@gmail.com. · Pôle femme et enfant, groupe hospitalier universitaire Paris Seine-Saint-Denis, site Jean-Verdier, avenue du 14-Juillet, 93140 Bondy, France; UFR SMBH, université Paris 13, Sorbonne Paris-Cité, 93000 Bobigny, France. · 5, avenue Émile-Deschnanel, 75007 Paris, France. ·Gynecol Obstet Fertil · Pubmed #27133917.

ABSTRACT: -- No abstract --

24 Editorial Evidence for lymphatic pathogenesis of endosalpingiosis: the more things change, the more they stay the same. 2016

Russell, Peter / Anderson, Lyndal. ·GynaePath, Douglass Hanly Moir Pathology, Macquarie Park, Sydney, Australia; The Department of Obstetrics Gynaecology and Neonatology, The University of Sydney, Australia. Electronic address: prussell@dhm.com.au. · Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia. ·Pathology · Pubmed #27020202.

ABSTRACT: -- No abstract --

25 Editorial [Endometriosis - the chameleon of gynecology]. 2016

Zanetti Dällenbach, Rosanna. ·1 Gynäkologie und Gynäkologische Onkologie, Universitätsspital Basel. ·Praxis (Bern 1994) · Pubmed #26934006.

ABSTRACT: -- No abstract --

Next